Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4983437 | 0.69 | KDM4E (0.37) | POLBAPOBEC3GCYP1A2KMT2AMEN1 | |
| SCHEMBL4988334 | 0.69 | TSHR (0.40) | POLBAPOBEC3GKMT2AMEN1LMNA | |
| SCHEMBL4987251 | 0.66 | HSP90AB1 (0.37) | — | |
| SCHEMBL6636926 | 0.65 | MAPT (0.38) | POLBCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4986807 | 0.64 | — | — | |
| SCHEMBL4927303 | 0.62 | — | — | |
| SCHEMBL1885381 | 0.61 | POLB (0.65) | POLBAPOBEC3GKMT2AMEN1THRB | |
| SCHEMBL2091818 | 0.61 | SLC6A4 (0.30) | — | |
| SCHEMBL21711153 | 0.61 | POLB (0.43) | POLBAPOBEC3GCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4979966 | 0.61 | HSP90AB1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6509362-B2 | Cholesteryl acyl transferase (ACAT) inhibitors; treatment of hyperlipidaemia and atherosclerosis. | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2003-01-21 | — | — | US | claimed |
| US-6452008-B2 | 3-UREA COMPOUND FROM THE 3-AMIDO COMPOUND WITHOUT AZIDATION PROCESS WHICH HAS RISK OF EXPLOSION; REACTION WITH HYPOCHLORITE, HYPOBROMITE OR LEAD TETRAACETATE AND THEN AN AMINE; ACAT INHIBITOR | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-09-17 | — | — | US | claimed |
| US-20020068739-A1 | New N-phenylamide and N-pyridylamide derivatives, method of preparing them and pharmaceutical compositions containing them | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2002-06-06 | — | — | US | claimed |
| US-6339097-B1 | FOR THERAPY OF HYPERLIPIDAEMIA AND ATHEROSCLEROSIS; CHOLESTERYL ACYL TRANSFERASE (ACAT) INHIBITORS | MERCK PATENT GMBH (DE) | 2002-01-15 | — | — | US | claimed |
| EP-1040109-A1 | N-PHENYLAMIDE AND N-PYRIDYLAMIDE DERIVATIVES, METHOD OF PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK PATENT GmbH (DE) | 2000-10-04 | — | — | EP | claimed |
| WO-1999033825-A1 | N-PHENYLAMIDE AND N-PYRIDYLAMIDE DERIVATIVES, METHOD OF PREPARING THEM AND PHARMACEUTICAL COMPOSITONS CONTAINING THEM | MERCK PATENT GMBH (DE) | 1999-07-08 | — | — | WO | claimed |
| EP-0609960-B1 | New N-heteroarylamide derivatives as inhibitors of acyl coenzyme A: cholestrol acyl transferase | PFIZER (US) | 1999-03-03 | — | — | EP | claimed |
| EP-0623112-B1 | 4-Phenyl-3-(heteroarylureido)-1,2-dihydro-2-oxoquinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents | PFIZER (US) | 1998-12-30 | — | — | EP | claimed |
| US-5596001-A | 4-aryl-3-(heteroarylureido)quinoline derivatves | PFIZER INC. (US) | 1997-01-21 | — | — | US | claimed |
| EP-0590094-A1 | 4-ARYL-3-(HETEROARYLUREIDO)QUINOLINE DERIVATIVES | PFIZER INC. (US) | 1994-04-06 | — | — | EP | claimed |
| WO-1992019614-A1 | 4-ARYL-3-(HETEROARYLUREIDO)QUINOLINE DERIVATIVES | PFIZER INC. (US) | 1992-11-12 | — | — | WO | claimed |
| US-7414066-B2 | Amide compounds and medications containing the same technical field | KOWA COMPANY LTD. (JP) | 2008-08-19 | — | — | US | disclosed |
| US-7393866-B2 | Amide compounds and medications containing the same | KOWA COMPANY, LTD. (JP) | 2008-07-01 | — | — | US | disclosed |
| EP-0979823-B1 | NOVEL AMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | KOWA CO (JP) | 2006-03-29 | — | — | EP | disclosed |
| US-20050131001-A1 | Novel amide compounds and medications containing the same technical field | KOWA COMPANY LTD. (JP) | 2005-06-16 | — | — | US | disclosed |
| EP-0609960-A1 | New N-heteroarylamide derivatives as inhibitors of acyl coenzyme A: cholestrol acyl transferase | PFIZER INC. (US) | 1994-08-10 | — | — | EP | disclosed |
| WO-1993024458-A1 | NEW N-ARYL AND N-HETEROARYLUREA DERIVATIVES AS INHIBITORS OF ACYL COENZYME A:CHOLESTEROL ACYL TRANSFERASE (ACAT) | PFIZER INC. (US) | 1993-12-09 | — | — | WO | disclosed |
| WO-1993015058-A1 | 4-ARYL-3-(HETEROARYLUREIDO)-1,2-DIHYDRO-2-OXO-QUINOLINE DERIVATIVES AS ANTIHYPERCHOLESTEROLEMIC AND ANTIATHEROSCLEROTIC AGENTS | PFIZER INC. (US) | 1993-08-05 | — | — | WO | disclosed |
| WO-1992019614-A1 | 4-ARYL-3-(HETEROARYLUREIDO)QUINOLINE DERIVATIVES | PFIZER INC. (US) | 1992-11-12 | — | — | WO | disclosed |
| EP-0418071-A2 | New N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase | PFIZER INC. (US) | 1991-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068739-A1 | New N-phenylamide and N-pyridylamide derivatives, method of preparing them and pharmaceutical compositions containing them | ACAT2, LCAT, ACAT1 | POLB 3111/4885APOBEC3G 3519/4885CYP1A2 99/4885 |
| US-20050131001-A1 | Novel amide compounds and medications containing the same technical field | ACAT2, SULT2A1, ACAT1 | POLB 4033/4885APOBEC3G 4870/4885CYP1A2 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.